Darwin Wealth Management’s VanEck Biotech ETF BBH Stock Holding History

Darwin Wealth Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$940	Buy	+5	New	+$963	﹤0.01%	540

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

Darwin Wealth Management's BBH Position: Q1 2026 in Review

Darwin Wealth Management opened a new position in VanEck Biotech ETF (BBH) in Q1 2026: 5 shares worth $940. The stake represents ﹤0.01% of the portfolio and ranks #540 among its holdings.

112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

Darwin Wealth Management held 5 shares of VanEck Biotech ETF worth $940 as of Q1 2026.
VanEck Biotech ETF was a new Darwin Wealth Management position in Q1 2026.
VanEck Biotech ETF made up ﹤0.01% of Darwin Wealth Management's portfolio in Q1 2026, its #540 holding.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Darwin Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.